For research use only. Not for therapeutic Use.
Iopromide is a low osmolar, non-ionic contrast agent for intravascular use. Iopromide is a molecule used as a contrast medium.
| Catalog Number | R011237 |
| CAS Number | 73334-07-3 |
| Synonyms | N,N’-Bis(2,3-Dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methyl-1,3-benzenedicarboxamide; Iopromidum; SHL 414C; Ultravist; Ultravist 300; Ultravist 370; ZK 35760; ? |
| Molecular Formula | C18H24I3N3O8 |
| Purity | ≥95% |
| Storage | -20°C |
| IUPAC Name | 1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(2-methoxyacetyl)amino]-3-N-methylbenzene-1,3-dicarboxamide |
| InChI | InChI=1S/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29) |
| InChIKey | DGAIEPBNLOQYER-UHFFFAOYSA-N |
| SMILES | CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)NC(=O)COC)I |
| Reference | </br>1:Comparison of Iodixanol and Iopromide in Patients With Renal Insufficiency and Congestive Heart Failure Undergoing Coronary Angiography by Hemodynamic Monitoring. Qian G, Yang YQ, Dong W, Cao F, Chen YD.Angiology. 2017 Jan 1:3319717701868. doi: 10.1177/0003319717701868. [Epub ahead of print] PMID: 28401790 </br>2:Tailoring partially reduced graphene oxide as redox mediator for enhanced biotransformation of iopromide under methanogenic and sulfate-reducing conditions. Toral-Sánchez E, Rangel-Mendez JR, Ascacio Valdés JA, Aguilar CN, Cervantes FJ.Bioresour Technol. 2016 Oct 22;223:269-276. doi: 10.1016/j.biortech.2016.10.062. [Epub ahead of print] PMID: 27969578 </br>3:Erratum to: Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial. Achenbach S, Paul JF, Laurent F, Becker HC, Rengo M, Caudron J, Leschka S, Vignaux O, Knobloch G, Benea G, Schlosser T, Andreu J, Cabeza B, Jacquier A, Souto M, Revel D, Qanadli SD, Cademartiri F; X-ACT Study Group..Eur Radiol. 2017 Feb;27(2):831. doi: 10.1007/s00330-016-4557-2. No abstract available. PMID: 27631105 </br>4:Comparative assessment of image quality for coronary CT angiography with iobitridol and two contrast agents with higher iodine concentrations: iopromide and iomeprol. A multicentre randomized double-blind trial. Achenbach S, Paul JF, Laurent F, Becker HC, Rengo M, Caudron J, Leschka S, Vignaux O, Knobloch G, Benea G, Schlosser T, Andreu J, Cabeza B, Jacquier A, Souto M, Revel D, Qanadli SD, Cademartiri F; X-ACT Study Group..Eur Radiol. 2017 Feb;27(2):821-830. doi: 10.1007/s00330-016-4437-9. Epub 2016 Jun 7. Erratum in: Eur Radiol. 2017 Feb;27(2):831. PMID: 27271922 Free PMC Article</br>5:Immobilization of metal-humic acid complexes in anaerobic granular sludge for their application as solid-phase redox mediators in the biotransformation of iopromide in UASB reactors. Cruz-Zavala AS, Pat-Espadas AM, Rangel-Mendez JR, Chazaro-Ruiz LF, Ascacio-Valdes JA, Aguilar CN, Cervantes FJ.Bioresour Technol. 2016 May;207:39-45. doi: 10.1016/j.biortech.2016.01.125. Epub 2016 Feb 8. PMID: 26868154 </br>6:Safety and efficacy of a novel iopromide-based paclitaxel-eluting balloon following bare metal stent implantation in rabbit aorta abdominalis. Zhu Z, Han H, Zhu J, Zhang J, Du R, Ni J, Ying C, An X, Zhang R.Biomed Mater Eng. 2015;26(1-2):79-88. doi: 10.3233/BME-151551. PMID: 26484558 Free PMC Article</br>7:Biodegradability of iopromide products after UV/H₂O₂ advanced oxidation. Keen OS, Love NG, Aga DS, Linden KG.Chemosphere. 2016 Feb;144:989-94. doi: 10.1016/j.chemosphere.2015.09.072. Epub 2015 Oct 2. PMID: 26433937 </br>8:A comparison of iopromide and iopamidol, two acidoCEST MRI contrast media that measure tumor extracellular pH. Moon BF, Jones KM, Chen LQ, Liu P, Randtke EA, Howison CM, Pagel MD.Contrast Media Mol Imaging. 2015 Nov-Dec;10(6):446-55. doi: 10.1002/cmmi.1647. Epub 2015 Jun 25. PMID: 26108564 Free PMC Article</br>9:Safety and tolerability of iopromide in patients undergoing cardiac catheterization: real-world multicenter experience with 17,513 patients from the TRUST trial. Chen JY, Liu Y, Zhou YL, Tan N, Zhang B, Chen PY, Chen LB.Int J Cardiovasc Imaging. 2015 Oct;31(7):1281-91. doi: 10.1007/s10554-015-0688-9. Epub 2015 Jun 10. PMID: 26058857 </br>10:Measuring the reactivity of commercially available zero-valent iron nanoparticles used for environmental remediation with iopromide. Schmid D, Micić V, Laumann S, Hofmann T.J Contam Hydrol. 2015 Oct;181:36-45. doi: 10.1016/j.jconhyd.2015.01.006. Epub 2015 Feb 14. PMID: 25708601 |
